Champions Oncology, Inc.
CSBR- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000771856
No open-market purchases or sales by Champions Oncology, Inc. insiders were filed in the last 90 days; 28 institutions reported holding it in 13F filings for Q2 2026, worth $36.3M in total; no superinvestor holds it.
Q4 2021 vs. Q3 2021
How the institutions holding Champions Oncology, Inc. changed between Q3 2021 and Q4 2021.
All holders in Q4 2021All holders in Q3 2021
| Measure | Q3 2021 | Q4 2021 | Change |
|---|---|---|---|
| Holders | 35 | 31 | −4 |
| Shares | 6.28M | 6.21M | −71.8K (−1.1%) |
| Value | $64.1M | $51.7M | −$12.4M (−19.3%) |
New holders (4)
Institutions that held Champions Oncology, Inc. at the end of Q4 2021 but not at the end of Q3 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Ameriprise Financial Inc | 83,032 | $664.0K | 0.00% |
| Masso Torrence Wealth Management Inc. | 1,000 | $8.00K | 0.01% |
| UBS Group AG | 280 | $2.00K | 0.00% |
| Bank of America Corp | 147 | $1.00K | 0.00% |
Sold out (8)
Institutions that held Champions Oncology, Inc. at the end of Q3 2021 and filed for Q4 2021 without it.
| Institution | Shares, Q3 2021 | Value, Q3 2021 |
|---|---|---|
| Bank of Montreal | 97,903 | $1.02M |
| Ergoteles LLC | 30,565 | $312.0K |
| HRT Financial LP | 12,541 | $128.0K |
| Federated Hermes, Inc. | 5,894 | $59.0K |
| Barclays PLC | 818 | $8.00K |
| Total Clarity Wealth Management, Inc. | 713 | $7.00K |
| Tower Research Capital LLC (TRC) | 117 | $1.00K |
| BNP Paribas Arbitrage, SA | 45 | $459 |